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ORIGINAL ARTICLE
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Jochumseng, Tonje Johansenh, Lise Grupe Larseni, Marianne Waldstrømf,j and Elsebeth Lyngea,b
aCenter for Epidemiological research, Nykøbing Falster Hospital, Nykøbing Falster, Denmark; bDepartment of Public Health, University of
Copenhagen, Copenhagen, Denmark; cDepartment of Public Health Programmes, Randers Regional Hospital, Central Denmark Region,
Randers, Denmark; dDepartment of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; eDepartment of Pathology, Aalborg
University Hospital, Aalborg, Denmark; fDepartment of Pathology, Vejle Sygehus, Vejle, Denmark; gDepartment of Gynecology and
Obstetrics, Odense University Hospital, Odense C, Denmark; hDepartment of Pathology, Randers Regional Hospital, Central Denmark Region,
Randers, Denmark; iDepartment of Pathology, Zealand University Hospital, Naestved, Denmark; jInstitute of Regional Health Research,
University of Southern Denmark, Odense, Denmark
ABSTRACT
Objective: Cytology findings of atypical squamous cells of unknown significance (ASCUS) or low-grade
squamous intraepithelial lesion (LSIL) are common among women under 30, but evidence on best
management strategy is insufficient. We therefore investigated how different management strategies
used in Denmark influenced biopsy rates and detection of cervical intraepithelial neoplasia (CIN).
Methods: Register-based cohort study including Danish women aged less than 30 years and born
1980–95, with ASCUS/LSIL as their first abnormal cervical cytology in 2008–16. Rates and relative risks
(RR) of biopsy and detection of CIN3þ, CIN2 and<CIN2 during two years follow-up were compared
between women referred directly to colposcopy after ASCUS/LSIL or undergoing additional testing,
including mRNA or DNA test for high risk HPV or repeat cytology.
Results: 19,946 women with ASCUS and 19,825 with LSIL were included in the study of whom 92%
had adequate information about follow-up. Among women referred directly to biopsy, CIN3þ was
detected among 21%, CIN2 in 17%, while 62% had<CIN2. Repeating cytology after 6months reduced
the biopsy rate to 44% of which 53% had<CIN2. Biopsy rates with HPV test were 67% for DNA test,
77% with 14-type mRNA test and 58% with 5-type mRNA test. The detection of CIN3þ was somewhat
higher, between 13% and 14% for the three HPV tests vs. 11% with repeat cytology. However, the
detection of<CIN2 (not indicating treatment) also increased with RR 2.11 (95% CI 2.01–2.21) for 14-
type mRNA test, 1.35 (95% CI 1.29–1.41) for 5-type mRNA test, and 1.86 (95% CI 1.76–1.97) with HPV
DNA test.
Conclusions: The choice of management strategy influences both the detection rate for severe lesions
(CIN3þ) and the proportion of women followed up for potentially insignificant findings.
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Cervical screening with cytology has helped reduce cervical
cancer incidence and mortality in high-income countries [1].
In countries with organized screening programs, women
with normal cytology will be recalled for screening after a
time period depending on age and national/local recommen-
dations, while women with high-grade intraepithelial lesion
(HSIL) are recommended further assessment, including col-
poscopy and supplementary testing, including biopsy or
endocervical abrasio, to verify if cervical intraepithelial neo-
plasia (CIN) is present [2].
An organized cervical screening program aims to obtain
the best possible balance between reducing the risk of
cervical cancer and limiting overmanagement. Although
many countries are adopting HPV test as a primary screening
test, this is usually not recommended for women under the
age of 30 years who will still be screened with cytology, also
in Denmark [3]. However, the positivity rate for cytology is
quite high in this age group and therefore management
strategy becomes essential. The optimal strategy is not fully
established and probably depends on the woman’s age [2].
Women with atypical cells of unknown significance (ASCUS)
or low-grade squamous intraepithelial lesions (LSIL) are at
much lower risk of having CIN2þ than women with HSIL.
Referral of all women with ASCUS or LSIL directly to colpos-
copy would result in overmanagement and overtreatment,
CONTACT Gry St-Martin grys@regionsjaelland.dk Center for Epidemiological Research, Nykøbing Falster Hospital, Ejegodvej 63, Nykøbing Falster
4800, Denmark
Supplemental data for this article can be accessed here.
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in
any way.
ACTA ONCOLOGICA
2021, VOL. 60, NO. 4, 444–451
https://doi.org/10.1080/0284186X.2020.1831061
and constitute a burden for women in terms of inconveni-
ence and worry and in risks related to biopsy taking. In add-
ition, it may be an inappropriate use of healthcare resources.
Additional testing or triage of women with ASCUS or LSIL is
therefore recommended prior to referral for colposcopy. In
this light, the objective of the present study was to examine
the outcome of different strategies used in Denmark for
women below 30 years of age with ASCUS or LSIL.
Material and methods
Data and definitions
The study was a register-based, retrospective cohort study
set in Denmark. All residents in Denmark are assigned a
unique personal identifier which allows for cross linking of
official healthcare and other registers. Women born in 1980
to 1995 and resident in Denmark through to study end in
2018 were identified through the Civil Registration System
[4]. For these women, cervical pathology results were
retrieved in the Danish Pathology Register (DPR) [5]. This
register contains all cytology and histology diagnoses with
SNOMED codes from all pathology departments in Denmark,
and was established in 1997. Cervical cytology is classified
according to the Bethesda system and histology from the
cervical region according to the CIN classification. Women
were included in the study if they had a cervical cytology
sample diagnosed with ASCUS or LSIL between 2008 and
2016, were below age 30, with no previous abnormal cervical
pathology result and no histology sample taken on the same
date as the index cytology sample. This was the index sam-
ple. We included the index sample and all cervical pathology
and HPV results for the subsequent 2 years.
National screening guidelines were published in 2007 [3].
Consequently, we included index samples from 1st January
2008 to 31st December 2016 allowing for two years of fol-
low-up (see Lexis diagram in Suppl. fig. 1). If more than one
histology diagnosis was recorded for a woman during the
two years, the most severe was used.
In Denmark, national recommendations for cervical cancer
screening are published by the Danish Health Authority, but
the screening program is implemented by the five regions of
the country, and the recommendations are not legally bind-
ing. All regions invite women according to the guidelines,
i.e., cytology screening every three years from age
23–49 years and every five years until age 59 years, followed
by a primary HPV-test (“exit test”) between age 60 and
64 years, five years after the last cytology test. For women
aged less than 30 years with ASCUS or LSIL, the Danish
guidelines recommend either mRNA HPV test of the ASCUS/
LSIL sample or repeat cytology after 6months. For women
30 years or older, HPV DNA test is an additional option for
ASCUS [3,6]. In addition to the recommended methods,
some pathology departments have periodically used HPV-
DNA test also for women under 30 years, and/or for LSIL.
Test methods were introduced and/or changed gradually
and more than one strategy may have been in use simultan-
eously in the same department. We therefore grouped
women based on the actual tests performed as per the
pathology register. For HPV tests, the register reports that
HPV test was performed, and in the majority of cases,
whether DNA or mRNA test was used. However, which DNA
or mRNA test was used, is not coded in the register. For
mRNA tests, we were able to classify into 5-type and 14-type
mRNA test groups based on information from the depart-
ments on assay used at that point in time. In total, we identi-
fied 5 main strategies: repeat cytology, 14-type mRNA test, 5-
type mRNA test, DNA test (any assay), or direct referral to col-
poscopy (see table in supplement for an overview of the labo-
ratories and their main recommended strategies). Women
who could not be classified into any of the five groups were
labeled unclassified. Furthermore, we subdivided each group
based on whether or not the woman had been adequately
followed up, and women lacking follow-up were excluded
from the analysis of outcomes. Table 1 shows the criteria for
each group.
Statistics
We calculated the proportion of women followed up with
each strategy by year and index diagnosis, and the propor-
tion of HPV tests that were positive by test method (5-type
mRNA/14-type mRNA/DNA HPV test) and index diagnosis.
The main analysis was the comparison of outcomes
between the different follow-up strategies. The outcomes
included were:
 Biopsy: women with a cervical biopsy histology result in
the DPR
 CIN3þ: women with a histology result of CIN3 or cervical
cancer in DPR
 CIN2: women with histology result of CIN2 in DPR
 <CIN2: women with histology result of CIN1, normal, or
no intraepithelial lesions in DPR
These groups reflect the different follow-up options.
Conization is recommended for CIN3þ, while not recom-
mended for normal and CIN1 biopsy finding, which should
be followed up after 6–12months. For CIN2 the recommen-
dation changed in 2012 from conization to follow-up.
We calculated the number and proportion of women with
each outcome during two years following initial ASCUS or
LSIL test for each follow-up strategy. For women undergoing
HPV test or direct referral, risk ratios with 95% confidence
intervals (CI) were calculated for each outcome relative to
those who underwent repeat cytology. Results were adjusted
for year of birth to account for variation between the birth
cohorts in HPV vaccination rates and age at vaccination [7].
A consequence of a follow-up period of two years may be
that some samples not resulting from the initial screening
episode (the index sample) are included. Although we con-
sidered this less likely, given the recommended screening
interval of 3 years, we repeated the analysis considering
9months of follow-up only. Women under 23 years are not
invited for screening through the Danish program and may
differ from women screened on invitation, so we repeated
the analyses only for women aged 23 and above. SAS 9.4
and Stata IC 15.1 were used for the analysis.
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Results
A total of 39,771 women were included in the study, 19,946
with ASCUS and 19,825 with LSIL. The median age was
24.1 years (range 14–29 years), and 31,918 (80%) were
23–29 years when the index sample was collected. The pro-
portion of women belonging to birth cohorts offered HPV-
vaccination through the childhood immunization program
(birth years 1993–95) was 6.7%.
Overall, about half of the women had repeat cytology, 46%
of ASCUS and 57% of LSIL (Table 2). HPV DNA testing was
used more often for ASCUS than LSIL; and 2,158 women (5.4%)
were unclassifiable, including 1,875 without repeat cytology
and no HPV-test of index sample, and 283 with an unspecified
HPV test. The proportion with repeat cytology declined over
time from 79% in 2008 to 34% in 2015, reflecting a gradual
introduction of HPV testing. In 2016, the use of DNA testing for
ASCUS declined and the 5-type mRNA test went out of use in
Denmark. Consequently the proportion with repeat cytology
increased to 52% (data not shown). The proportion of samples
testing positive for HPV depended on the index diagnosis and
test method, being higher for LSIL and DNA test and lower for
ASCUS and 5-type mRNA test (Table 3).
In total 36,453 (92%) could be classified according to the
5 strategies and had adequate follow-up within 2 years
(Table 4). The proportion of women undergoing biopsy was
higher with HPV test than with repeat cytology and highest






Repeat cytology  No HPV test performed on the
index sample
AND
 Next sample in pathology register
was cytology
AND
 No histology sample was taken at
the time of repeat cytology
Either:
 Abnormal cytology on repeat
cytology
AND
 Subsequent histology sample
Or:
 Normal cytology on
repeat cytology
 Abnormal cytology on repeat
cytology
AND
 No additional samples in register
during 2 years
14-type mRNA test  hr-HPV mRNA test was performed
on the index cytology sample
AND
 Index date and laboratory where
14-type test was used
At least one more sample registered
after index
No tests beyond the index (according
to guideline, women with negative
mRNA-test should be retested with
cytology after 12months, so
regardless of mRNA result we
would expect additional test
within 2 years)
5-type mRNA test  hr-HPV mRNA test was performed
on the index cytology sample
AND
 Index date and laboratory where
5-type test was used
At least one more sample registered
after index
No tests beyond the index (women
with negative mRNA-test should
be retested with cytology after
12months, so regardless of mRNA
result we would expect additional
test within 2 years)
DNA  hr-HPV DNA test was performed
on the index cytology sample
Either:
 HPV DNA test negative
Or:
 HPV DNA test positive
AND
 at least one sample registered
after index
 HPV DNA test positive
AND
 no further tests beyond
index sample
Direct referral  Next cervical sample in the
pathology register was histology
(with or without cytology)
AND
 No HPV test was performed on
index sample
Women in this group were identified
based on the presence of a
histology result and so by
definition have all been
followed up
Unclassifiable Either:
 no HPV test on the index sample
AND
 no further tests beyond the
index sample
Or:
 HPV test on index sample but no
information on type (mRNA
or DNA)
All excluded from the analysis
Table 2. Women under 30 years with ASCUS or LSIL in Denmark 2008–2016
by index diagnosis and follow-up.
Follow-up ASCUS LSIL Total
Repeat cytology 9,604 48% 11,366 57% 20,970 53%
14-type mRNA test 1,647 8% 1,542 7.8% 3,189 8%
5-type mRNA test 3,306 17% 4,047 20% 7,353 19%
DNA 2,916 15% 839 4.2% 3,755 9%
Direct referral for colposcopy 1,439 7% 907 4.5% 2,346 6%
Not classified 1,034 5% 1,124 5.7% 2,158 5%
Total 19,946 100% 19,825 100% 39,771 100%
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for 14-type mRNA test at 77%, followed by DNA (67%), and
5-type mRNA test (58%). The detection of all histology results
increased with HPV triage, including non-severe lesions
(<CIN2) and normal biopsies. The same pattern was seen
when considering ASCUS or LSIL separately.
Correspondingly, the relative risks were above one for all
outcomes when HPV triage and direct referral were compared
with repeat cytology (Table 5). For 14-type mRNA test, DNA
test, and direct referral, the relative risks were higher
for<CIN2 than for CIN2 and CIN3þ. Adjustment for year of
birth and index diagnosis did not change these results.
Looking at ASCUS separately, the results followed the same
pattern, but for LSIL, the RR for<CIN2 when using HPV triage
was not elevated to the same extent. Figure 1 visualizes the
relative risks for the adjusted analysis presented in Table 5.
Repeating the analyses using only 9months of follow-up
resulted in a higher proportion of women lacking follow-up
(24%, mostly from the repeat cytology group) but did not
change the results of the analysis (data not shown).
Restricting the analysis to women aged 23 and above at index
did not change the results either (data not shown).
Discussion
Main findings
During the past decade, several strategies have been used in
Denmark for women below 30 years with ASCUS or LSIL. The
strategy used had an impact on the benefits and the harms
of cervical screening of these young women. The detection
Table 3. HPV test results by index diagnosis and HPV test method, excluding samples with unknown HPV test and/or unknown result.
ASCUS LSIL
Positive Negative Totala Positive Negative Totala
14-type mRNA test 1,131 69% 515 31% 1,646 1,209 78% 333 22% 1,542
5-type mRNA test 1,106 36% 1,964 64% 3,070 1,655 44% 2,136 56% 3,791
DNA test 2,165 75% 736 25% 2,901 745 90% 84 10% 829
Total 4,402 58% 3,215 42% 7,617 3,609 59% 2,553 41% 6,162
aTotals are lower than in Table 2 because results were missing for some samples.
Table 4. Biopsy rates and proportion with CIN3þ, CIN2, or< CIN2 in Danish women under 30 years with ASCUS or LSIL by management strategy and whether
















Number with ASCUS/LSIL 20.634 3.021 6.789 3.663 2.346 36.453 3.318 39.771
Number with biopsyb 9.022 2.314 3.929 2.454 2.346 20.065
% biopsy/(ASCUS/LSIL) 44% 77% 58% 67% 100% 55%
Number with CIN3þ 2.225 435 862 475 492 4.489
% CIN3þ/(ASCUS/LSIL) 11% 14% 13% 13% 21% 12%
% CIN3þ/biopsy 25% 19% 22% 19% 21% 22%
Number with CIN2 1.975 381 899 453 388 4.096
% CIN2/(ASCUS/LSIL) 10% 13% 13% 12% 17% 11%
% CIN2/biopsy 22% 16% 23% 18% 17% 20%
Number with< CIN2 4.797 1.496 2.147 1.521 1.445 11.406
% <CIN2/(ASCUS/LSIL) 23% 50% 32% 42% 62% 31%
% <CIN2/biopsy 53% 65% 55% 62% 62% 57%
Number with ASCUS 9.463 1.557 3.034 2.857 1.439 18.350 1.596 19.946
Number with biopsyb 3.657 1.138 1.587 1.918 1.439 9.739
% biopsy/ASCUS 39% 73% 52% 67% 100% 53%
Number with CIN3þ 1.070 257 367 347 384 2.425
% CIN3þ/ASCUS 11% 17% 12% 12% 27% 13%
% CIN3þ/biopsy 29% 23% 23% 18% 27% 25%
Number with CIN2 789 194 352 329 216 1880
% CIN2/ASCUS 8% 12% 12% 12% 15% 10%
% CIN2/biopsy 22% 17% 22% 17% 15% 19%
Number with< CIN2 1.786 686 860 1.238 833 5.403
% <CIN2/ASCUS 19% 44% 28% 43% 58% 29%
% <CIN2/biopsy 49% 60% 54% 65% 58% 55%
Number with LSIL 11.171 1.464 3.755 806 907 18.103 1.722 19.825
Number with biopsyb 5.365 1.176 2.342 536 907 10.326
% biopsy/LSIL 48% 80% 62% 67% 100% 57%
Number with CIN3þ 1.155 178 495 128 108 2.064
% CIN3þ/LSIL 10% 12% 13% 16% 12% 11%
% CIN3þ/biopsy 22% 15% 21% 24% 12% 20%
Number with CIN2 1.186 187 547 124 172 2.216
% CIN2/LSIL 11% 13% 15% 15% 19% 12%
% CIN2/biopsy 22% 16% 23% 23% 19% 21%
Number with< CIN2 3.011 810 1.287 283 612 6.003
% <CIN2/LSIL 27% 55% 34% 35% 67% 33%
% <CIN2/biopsy 56% 69% 55% 53% 67% 58%
ASCUS: Atypical cells of unknown significance; LSIL: low-grade squamous intraepithelial lesion; CIN: Cervical intraepithelial neoplasia.
aThese numbers only include women with adequate follow-up as per definition in Table 1 and are therefore lower than numbers in Table 2 which include all women.
bNumber with biopsy may be higher than the sum of histology diagnoses because some samples had unknown diagnosis.
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of CIN3þ was somewhat higher, 13% to 14% with HPV test-
ing vs. 11% with repeat cytology. Compared with repeat
cytology, HPV testing led to more women undergoing
biopsy, and more women had biopsies that turned out nor-
mal or with CIN1-2 which does not indicate treatment. Direct
referral to colposcopy led to as many as 62% of women
undergoing biopsies with<CIN2.
Except for 5-type mRNA test, the relative risks for biop-
sies with<CIN2 were higher than the relative risks for high
grade lesions, indicating overmanagement. The risk of hav-
ing biopsies not indicating treatment was approximately
doubled with 14-type mRNA test (2.11) or HPV DNA test
(1.86) and almost tripled with direct referral to colpos-
copy (2.80).
Table 5. Relative risk of CIN3þ, CIN2, <CIN2 for women with ASCUS or LSIL triaged with HPV-tests or referred directly for colposcopy vs. women with
repeat cytology.
14-type mRNA test vs repeat cytology 5-type mRNA test vs. repeat cytology DNA test vs repeat cytology Direct referral vs repeat cytology
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
All women – unadjusted/crude
CIN3þ 1.34 1.21–1.47 1.18 1.09–1.27 1.20 1.10–1.32 1.94 1.78–2.12
CIN2 1.32 1.19–1.46 1.38 1.28–1.49 1.29 1.17–1.42 1.73 1.56–1.91
<CIN2 2.13 2.04–2.23 1.36 1.30–1.42 1.79 1.71–1.87 2.65 2.54–2.76
All women – adjusted for birth year
CIN3þ 1.48 1.34–1.63 1.19 1.10–1.28 1.37 1.24–1.51 1.94 1.78–2.12
CIN2 1.31 1.18–1.46 1.37 1.27–1.48 1.30 1.18–1.44 1.73 1.56–1.91
<CIN2 2.07 1.97–2.17 1.35 1.29–1.41 1.72 1.63–1.80 2.66 2.55–2.77
All women – adjusted for index diagnosis
CIN3þ 1.33 1.21 1.46 1.18 1.09 1.27 1.18 1.08 1.30 1.9 1.74 2.08
CIN2 1.33 1.20 1.48 1.38 1.28 1.49 1.4 1.27 1.55 1.79 1.62 1.98
<CIN2 2.17 2.08 2.27 1.36 1.30 1.41 1.97 1.87 2.07 2.79 2.68 2.91
All women – adjusted for index diagnosis and birth year
CIN3þ 1.47 1.33–1.62 1.19 1.10–1.28 1.35 1.22–1.50 1.91 1.74–2.08
CIN2 1.34 1.20–1.49 1.37 1.27–1.48 1.43 1.29–1.59 1.79 1.62–1.98
<CIN2 2.11 2.01–2.21 1.35 1.29–1.41 1.86 1.76–1.97 2.80 2.68–2.92
ASCUS – unadjusted/crude
CIN3þ 1.46 1.29–1.65 1.07 0.96–1.20 1.07 0.96–1.20 2.36 2.13–2.61
CIN2 1.49 1.29–1.73 1.39 1.24–1.57 1.38 1.22–1.56 1.80 1.57–2.07
<CIN2 2.33 2.18–2.50 1.50 1.40–1.61 2.30 2.16–2.44 3.07 2.89–3.26
ASCUS – adjusted for birth year
CIN3þ 1.62 1.42–1.84 1.07 0.96–1.20 1.20 1.06–1.35 2.34 2.11–2.60
CIN2 1.52 1.30–1.78 1.38 1.23–1.57 1.43 1.25–1.63 1.80 1.57–2.08
<CIN2 2.21 2.04–2.38 1.49 1.39–1.60 2.15 2.01–2.29 3.07 2.89–3.27
LSIL – unadjusted/crude
CIN3þ 1.18 1.01–1.36 1.27 1.16–1.41 1.54 1.30–1.82 1.15 0.96–1.39
CIN2 1.20 1.04–1.39 1.37 1.25–1.51 1.45 1.22–1.72 1.79 1.55–2.06
<CIN2 2.05 1.94–2.17 1.27 1.20–1.34 1.30 1.18–1.44 2.50 2.37–2.64
LSIL – adjusted for birth year
CIN3þ 1.30 1.01–1.36 1.29 1.17–1.43 1.89 1.57–2.26 1.18 0.98–1.42
CIN2 1.19 1.03–1.38 1.36 1.24–1.50 1.43 1.19–1.71 1.78 1.54–2.06
<CIN2 2.04 1.92–2.16 1.27 1.20–1.34 1.30 1.17–1.44 2.51 2.37–2.65
















Figure 1. Relative risks for CIN3þ, CIN2 and< CIN2 with HPV test or direct referral to colposcopy compared to repeat cytology. Results adjusted for index diagnosis
and birth year.
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Other studies
Several studies have shown higher rates of either underlying
CIN2þ or higher rates of progression to CIN2þ or HSIL in
women with ASCUS or LSIL who are HPV positive than
women who are HPV negative [8,9]. A negative HPV test
thus serves to identify women at low risk who can safely
return to the screening program. However, studies also con-
firm that HPV-tests are often positive in ASCUS/LSIL, espe-
cially among younger women [10–13] and absolute rates of
CIN2þ are low, appr. 5–10% over 5 years in women under
30 years [13].
Several studies [13–15], a Cochrane review from 2013 [16]
and two recent metaanalyses [17,18] have reported increased
sensitivity for CIN2þ with HPV test, whether mRNA or DNA
compared to repeat cytology. In the Cochrane review, both
methods had similar specificity in ASCUS cases, but the spe-
cificity of DNA test in LSIL was significantly lower than that
of repeat cytology. In addition, the absolute specificity of
both methods was low, potentially leading to many unneces-
sary referrals and biopsies, especially in younger women. The
Cochrane review only included studies using the HC2 assay,
whereas assays used in Denmark may be more sensitive and
increase overmanagement [19].
Another Cochrane review compared immediate colpos-
copy to repeat cytology and found that immediate colpos-
copy led to increased detection of potentially significant as
well as insignificant lesions, as in our study, but also con-
cluded that over two years of cytological surveillance the
detection of severe lesions was similar to immediate colpos-
copy [20]. A Swedish study found that repeat cytology within
6months maintained a reduced risk for invasive cancer while
reducing the colposcopies for the youngest women in this
age group [21]
A meta-analysis on studies of 5-type mRNA tests con-
cluded that these tests reduce referrals to colposcopy and
overtreatment but due to their lower sensitivity compared to
other HPV tests cannot reliably exclude CIN2þ and therefore
women with ASCUS or LSIL and negative 5-type mRNA test
still need cytological follow-up [22]. This is in line with find-
ings from other settings [23–25]. Comparison of 14-type
mRNA test to DNA test has shown either comparable sensi-
tivity for CIN2þ [10] or slightly lower sensitivity of 14-type
mRNA test [26] and higher specificity of the 14-type mRNA
test. However, in a Norwegian study the detection rate of
CIN3þ were the same for the 5-type HPV mRNA test and a
14-type HPV DNA test [27].
Other options besides the ones in use in Denmark are
available and may offer advantages. One option is dual stain-
ing cytology which appears to lower the number of false
positives and increase the proportion of correct referrals for
colposcopy [11], although a model-based economic evalu-
ation of triage of ASC-US/LSIL in women 25–33 years, showed
HPV mRNA triage to be more cost-efficient than dual staining
[28]. Another option is so-called delayed triage, with HPV
testing performed at the time of the repeat cytology and not
on the initial ASCUS/LSIL sample. This was the approach
taken in Norway, when triage of ASCUS and LSIL was intro-
duced [12,29]. Comparing the previous routine (repeat
cytology only) to the new routine (repeat cytology and HPV
test), the new routine led to increase in referrals to colpos-
copy and increased detection rate of CIN2þ while rates fell
in women referred back to the screening program, indicating
better risk stratification but at the expense of more women
undergoing colposcopy and biopsy. Specificity was lowest
for women under 34 years, at 47% [12,29].
Clinical implications
Although most women with ASCUS, including those with
positive hr-HPV test, will never develop CIN3 or cancer, a
considerable proportion of all CIN3 diagnoses are made in
women whose initial screening result was ASCUS [16], indi-
cating the need for follow-up of these women. Repeated
cytological examination constitutes a burden to women and
the healthcare sector. On the other hand, referring all
women with ASCUS directly to colposcopy and possibly
biopsies result in overmanagement, as also indicated by our
study. A specific triage test with a low positivity rate trans-
lates into a low referral rate for colposcopy, which is very
appealing for triage situations. In our material, the 5-type
HPV mRNA test was the most specific triage test.
In current Danish guidelines, HPV positive cases are
referred for colposcopy. This may lead to overmanagement,
however, because many HPV infections and minor lesions
clear spontaneously. As in our study, the Cochrane review
reported high HPV positivity rates in LSIL. LSIL is a common
manifestation of HPV infection even in cases where the HPV
infection never progresses to more severe lesions or cancer,
and the ability of the test to distinguish between cases with
or without severe underlying lesions or risk for development
of such lesions is limited [16]. Correspondingly, our study has
shown that HPV test used this way, especially DNA test and
14-type mRNA test, leads to many unnecessary biopsies.
Additionally, not all CIN3 and only a minority of CIN2 pro-
gress to cancer so a substantial proportion of women will
still undergo biopsy and potentially conization unnecessarily,
even when referral to colposcopy is restricted to HPV-posi-
tive cases [30]. An alternative might be to use DNA test or
14-type mRNA test to identify which women with ASCUS/
LSIL need cytological follow-up after 6months rather than to
select women for colposcopy at their first occurrence of
ASCUS/LSIL, while using genotyping or 5-type mRNA test to
select women for immediate referral to colposcopy. In
Norway, in women with ASC-US/LSIL, only HPV type 16/18
positive are referred for colposcopy while other HPV-types
are followed-up with repeated HPV-testing after
12months [31].
The Danish guidelines recommend only HPV mRNA test
and not DNA test for women under age 30. However, our
results show similar outcome for the 14-type mRNA test and
DNA test and therefore do not support the general recom-
mendation to prefer an mRNA test to a DNA test in this age
group. The 5-type mRNA test is more specific according to
our results, but not currently in use in Denmark.
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Strengths and limitations
The availability of nationwide registers allowed us to have
population-based, complete data on women with ASCUS/
LSIL cervical samples and to base our observations on how
the triage strategies perform in practice and not in an experi-
mental study setting. In addition, this minimizes loss of fol-
low-up.
Conization would have been a relevant outcome but was
not included because the policy for conization changed over
the years from conization of CIN2þ to only CIN3þ, especially
for premenopausal women. This change was formalized in
2012 in new guidelines from the Danish Society for
Obstetrics and Gynecology, but implemented gradually
across the five Danish regions. The risk for conization there-
fore depends not only on histology result (and hence triage
method), but also on whether the more restrictive policy had
been adopted in a woman’s region of residence at the time
she was screened. Indeed, in our data, for women with an
index date before 1st January 2012, 42% of those with CIN2
as worst histology were conizised in contrast with 20% in
those with index date after 1st January 2012; and 17% after
January 2016.
Liquid based cytology (LBC) was introduced gradually
over the years, and so was the use of HPV triage. LBC imay
lead to detection of more intraepithelial lesions than conven-
tional cytology, especially ASCUS and LSIL [29,30] so the dif-
ferences in outcomes may therefore depend not only on the
triage method but also, at least in part, on whether conven-
tional or liquid based cytology was used. The cytology
method is documented only for a minority of samples, how-
ever, so we were unable to account for this in the analysis.
The pathology register does not hold information on
whether cytology sampling was due to invitation from the
screening program, opportunistic screening, or symptoms.
Conceivably, women referred directly to colposcopy (which is
not in line with official recommendations) may have con-
sulted their GP for symptoms or they may have been
referred based on observations made by the GP at the rou-
tine screening. Consequently, they may not be completely
comparable to women in the other groups which may, at
least in part, explain the higher rates of CIN seen with direct
referral. This may in particular be the case for women under
23 years not invited to screening. We therefore repeated the
analysis only for women aged 23 and above, which did not
change the results (data not shown).
It is possible that some women had not completed fol-
low-up within the two years, especially women in the repeat
cytology group. When the repeat cytology is normal, the rec-
ommendation is for a third cytology after 12months (i.e.,
18months after the initial cytology) and referral to colpos-
copy within 3months (21months after the initial sample) if
ASCUSþ. Biopsy rates and proportion of women diagnosed
with any degree of CIN may therefore be underestimated if
delays in obtaining pathology results and booking new
appointments led the 21months period to extend beyond
the 2 years of follow-up. However, we expect that most
women would be retested within the recommended time
frame and in addition, extending the follow-up to 3 years
would result in inclusion of samples taken as a result of
reaching the next screening invitation and not as follow-up
of the index sample.
Finally, this study covered a historical period where most
women had not been vaccinated against HPV prior to reach-
ing screening age. From 2016, birth cohorts vaccinated
through the childhood immunization program started enter-
ing the screening program, and rates of HPV infection, cyto-
logical lesions and CIN are likely to change in the future with
implications for screening and triage strategies.
Conclusion
In conclusion, the optimal strategy for assessment of ASCUS
and LSIL is still not clear, and the choice will depend on the
health authorities’ and women’s preferred balance between
benefits and harms. Based on our study, repeat cytology or
triage with 5-type mRNA test seems to offer advantages
compared to HPV testing in terms of fewer unnecessary
biopsies. Alternatively, using HPV testing to select women
with ASCUS/LSIL for repeat cytology (rather than for immedi-
ate referral to colpocopy) might be a suitable option. More
research, including on women’s preferences and possibly tri-
age strategies not currently in use in the Danish program, is
needed to establish the optimal management strategy for
young women with ASCUS or LSIL.
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